NCT00871923 2021-09-16
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
23 trialsNCT02689336 2019-09-09
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Washington University School of Medicine
Phase 2 Withdrawn
NCT01182350 2019-09-04
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00720356 2018-10-26
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Northwestern University
Phase 2 Completed
NCT02233049 2018-07-23
BIOMEDE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT02655536 2018-07-10
BRILLIANT
National Taiwan University Hospital
Phase 2 Unknown
NCT00187486 2017-09-05
Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
University of California, San Francisco
Phase 2 Completed
NCT00086879 2017-07-27
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00947167 2017-03-03
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT01578668 2015-01-26
Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
Guangzhou Medical University
Phase 2 Completed
NCT01763385 2014-12-23
TRACTS
Wu Jieping Medical Foundation
Phase 2 Unknown
NCT00525525 2014-11-14
AVF4120s
University of California, San Francisco
Phase 2 Completed
NCT00337883 2014-03-04
A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
Genentech, Inc.
Phase 2 Completed
NCT00054496 2014-01-10
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00672243 2013-08-07
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Duke University
Phase 2 Completed
NCT00039494 2013-08-02
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00387894 2013-06-04
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
University of California, San Francisco
Phase 2 Terminated
NCT00671970 2013-05-13
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Duke University
Phase 2 Completed
NCT00274833 2012-12-06
Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00554775 2011-12-12
TACTIC
University College, London
Phase 2 Terminated
NCT00830245 2011-07-26
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
Clinical Research Center for Solid Tumor, Korea
Phase 2 Terminated
NCT01130779 2010-05-26
The Continuation of Erlotinib
Samsung Medical Center
Phase 2 Unknown
NCT00663689 2008-04-22
Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer
GuangdongPPH
Phase 2 Unknown